Butterfly Network announced it launched its third-generation handheld point-of-care ultrasound (POCUS) system in Europe. The semiconductor-based, single-probe, whole-body ultrasound offering iQ3 features a brand-new ergonomic design and provides double the data processing speed compared to previous generations. The FDA cleared the iQ3 system in January and it now has CE mark approval in Europe.
Burlington, Massachusetts–based Butterfly began the U.S. rollout for this system in February. The company powers the iQ3 with its most advanced semiconductor chip, featuring a data transfer rate that doubles its predecessor’s. This results in enhanced image quality and faster micro-beamforming for advanced 3D capabilities called iQ Slice and iQFan.
Related: Ocutech launches device to aid with vision loss after stroke and brain injury
Other key upgrades include a 17% smaller probe face and a 7% shorter probe with ergonomic weight distribution. iQ3 has three configurable control buttons and a 2.5-times faster charge time with up to two hours of thermal run time.
“After witnessing the enthusiastic uptake of Butterfly iQ3 in the United States and Canada over the past few months, we’ve been eager to receive the regulatory approval to introduce this high-performance device in Europe,” said Joseph DeVivo, Butterfly Network president, CEO, and chair. “We’re confident that the enhanced image quality and advanced features of Butterfly iQ3 will bring significant value to healthcare providers across Europe, supporting them in delivering quality patient care.
“Our mission to democratize ultrasound continues, and we are excited to continue seeing the promise of Butterfly iQ3 benefit new regions.”
